Your browser is no longer supported. Please, upgrade your browser.
Settings
DERM Dermira, Inc. daily Stock Chart
DERM [NASD]
Dermira, Inc.
Index- P/E- EPS (ttm)-4.91 Insider Own0.60% Shs Outstand47.28M Perf Week-8.05%
Market Cap459.09M Forward P/E- EPS next Y-5.59 Insider Trans19.26% Shs Float39.68M Perf Month-24.02%
Income-205.70M PEG- EPS next Q-1.77 Inst Own86.40% Short Float9.78% Perf Quarter0.73%
Sales41.40M P/S11.09 EPS this Y-177.30% Inst Trans3.45% Short Ratio7.76 Perf Half Y-4.80%
Book/sh1.28 P/B7.59 EPS next Y-6.10% ROA-41.90% Target Price17.00 Perf Year-59.51%
Cash/sh8.01 P/C1.21 EPS next 5Y- ROE-185.40% 52W Range6.98 - 31.42 Perf YTD-65.08%
Dividend- P/FCF- EPS past 5Y-52.30% ROI-70.00% 52W High-69.10% Beta0.92
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin99.40% 52W Low39.11% ATR0.91
Employees162 Current Ratio5.30 Sales Q/Q-36.40% Oper. Margin- RSI (14)35.52 Volatility8.72% 8.43%
OptionableYes Debt/Eq5.22 EPS Q/Q63.20% Profit Margin- Rel Volume1.38 Prev Close10.13
ShortableYes LT Debt/Eq5.22 EarningsNov 07 AMC Payout- Avg Volume500.00K Price9.71
Recom2.30 SMA20-17.48% SMA50-15.18% SMA200-17.22% Volume689,997 Change-4.15%
Mar-06-18Downgrade Guggenheim Buy → Neutral
Mar-05-18Downgrade Mizuho Buy → Neutral $39 → $9
Mar-05-18Downgrade Mizuho Buy → Neutral
Dec-12-17Reiterated Mizuho Buy $43 → $39
Dec-06-17Initiated Guggenheim Buy $30
Nov-07-17Reiterated Needham Buy $46 → $43
Jun-30-17Initiated Evercore ISI Outperform $48
May-25-17Reiterated Mizuho Buy $42 → $40
Mar-31-17Initiated Mizuho Buy $42
Mar-16-17Initiated Raymond James Underperform
Jun-02-16Reiterated Needham Buy $42 → $46
May-11-16Reiterated Needham Buy $38 → $42
Jan-08-16Reiterated Needham Buy $33 → $38
Dec-18-15Upgrade Citigroup Neutral → Buy
Aug-17-15Reiterated Needham Buy $23 → $33
Oct-28-14Initiated Needham Buy $23
Nov-09-18 11:27AM  Edited Transcript of DERM earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -11.11%
Nov-08-18 04:05PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-07-18 07:00PM  Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:01PM  Dermira Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-31-18 04:01PM  Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018 GlobeNewswire
Oct-23-18 04:01PM  Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis GlobeNewswire
Oct-17-18 07:25AM  Report: Exploring Fundamental Drivers Behind Dermira, California Resources, OGE Energy, Oasis Petroleum, Harmonic, and CBIZ New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-09-18 04:01PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Oct-02-18 08:30AM  Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin GlobeNewswire
Oct-01-18 07:30AM  Dermiras QBREXZA (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis GlobeNewswire +6.88%
Sep-25-18 08:00AM  Dermira to Present at Cantor 2018 Global Healthcare Conference GlobeNewswire
Sep-13-18 06:00AM  Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress GlobeNewswire
Sep-10-18 04:02PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-05-18 07:30AM  Dermira Provides Launch Readiness Update for QBREXZA (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis GlobeNewswire +5.91%
Aug-20-18 07:50AM  Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-08-18 08:14PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-06-18 06:05PM  Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:02PM  Dermira: 2Q Earnings Snapshot Associated Press
04:01PM  Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-10-18 04:01PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.47%
Jul-06-18 02:36PM  Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval Zacks +7.60%
Jul-02-18 08:36AM  Are Options Traders Betting on a Big Move in Dermira (DERM) Stock? Zacks
Jun-29-18 12:00PM  Dermira Shares Soar With FDA Approval of New Cloth TheStreet.com
11:38AM  FDA OKs first drug made to reduce excessive sweating Associated Press
08:36AM  FDA approves Dermira's wipe for excessive armpit sweating Reuters
07:05AM  Dermira's treatment for excessive armpit sweating gets U.S. approval Reuters
07:00AM  Dermira Receives FDA Approval for Qbrexza (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis GlobeNewswire
Jun-18-18 07:20AM  Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks ACCESSWIRE
Jun-08-18 04:01PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-05-18 08:30AM  Investor Expectations to Drive Momentum within Dermira, Atlassian, 51job, Sierra Wireless, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, and InterDigital Discovering Underlying Factors of Influence GlobeNewswire
May-31-18 08:07AM  Dermira, Upcoming FDA Decision on NDA, Analyst Review and Target ACCESSWIRE
May-30-18 04:01PM  Dermira to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
07:00AM  Wired News - Reata Pharma Presented Encouraging Interim Data from PHOENIX Trial Assessing Bardoxolone Methyl in Patients with ADPKD and IgA Nephropathy ACCESSWIRE
May-24-18 04:18PM  Here's Why Dermira Inc Stock Fell More Than 23% Today Motley Fool -22.61%
May-14-18 02:10PM  Schlumberger Is Among 7 Stocks Ready to Change Direction TheStreet.com +10.25%
08:30AM  Dermira to Host Analyst & Investor Day on May 24, 2018 GlobeNewswire
May-08-18 04:03PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-03-18 05:58PM  Dermira: 1Q Earnings Snapshot Associated Press
04:02PM  Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-02-18 08:00AM  Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living with the Condition in the U.S. GlobeNewswire
May-01-18 04:02PM  Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference GlobeNewswire
Apr-19-18 04:04PM  Christopher Horan Joins Dermira as Chief Technical Operations Officer GlobeNewswire
Apr-12-18 07:11PM  Will Dermira Incs (NASDAQ:DERM) Earnings Grow In The Years Ahead? Simply Wall St.
08:20AM  Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-11-18 04:05PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-20-18 08:00AM  Dermira to Present at 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-15-18 08:30AM  Market Trends Toward New Normal in Silver Standard Resources, Dermira, Colliers International Group, Canadian Pacific Railway, The Descartes Systems Group, and Westport Fuel Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -9.45%
Mar-14-18 07:30AM  Wired News Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer ACCESSWIRE
Mar-09-18 09:09AM  Your first trade for Friday, March 9 CNBC
07:45AM  Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails Zacks
Mar-08-18 04:05PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.05%
08:00AM  Dermira to Present at Cowen & Company 38th Annual Healthcare Conference GlobeNewswire
Mar-06-18 10:36AM  Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink Zacks +10.59%
08:33AM  Dermira shares drop 66% after surprise acne clinical trial failure MarketWatch
08:30AM  Todays Research Reports on Trending Tickers: Akorn and Dermira ACCESSWIRE
07:20AM  Heres What Really Just Happened With Dermira, Inc. (NASDAQ:DERM) Market Exclusive
Mar-05-18 04:54PM  Why Dermira, Community Health Systems, and BRF Slumped Today Motley Fool -65.86%
04:13PM  Why This Biotech Stock Just Lost Two-Thirds Of Its Value Investor's Business Daily
03:07PM  US Stocks Reverse Losses GuruFocus.com
01:03PM  Here's Why Dermira Fell as Much as 64.2% Today Motley Fool
12:55PM  Dermira Inc Stock Plunges on Acne Drug Failure InvestorPlace
11:24AM  Dermira Reminds Investors What Binary Means in Biotech Bloomberg
09:42AM  Dermira Inc (DERM) Runs Downhill on Back of Disappointing Clinical Results in Acne Vulgaris SmarterAnalyst
08:33AM  Dermira shares plummet 70% on news of acne drug failure MarketWatch
07:59AM  Dermiras Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints GlobeNewswire
Feb-23-18 05:00AM  Dermira reports 4Q loss Associated Press
Feb-22-18 04:01PM  Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
09:00AM  Are Options Traders Betting on a Big Move in Dermira (DERM) Stock? Zacks
Feb-17-18 06:30PM  New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology GlobeNewswire
Feb-12-18 08:30AM  Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference GlobeNewswire
Feb-09-18 08:30AM  Dermira to Present at Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-08-18 04:01PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.76%
Jan-31-18 08:30AM  Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis GlobeNewswire
Jan-29-18 08:39AM  Are Options Traders Betting on a Big Move in Dermira (DERM) Stock? Zacks
Jan-09-18 08:07AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit
Jan-02-18 08:04AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit
Dec-28-17 12:02PM  ETFs with exposure to Dermira, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:46AM  Dermira, Inc. :DERM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-12-17 07:23AM  Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : December 12, 2017 Capital Cube
Nov-28-17 04:26PM  Dermira Inc (DERM): What Are The Future Prospects? Simply Wall St.
Nov-27-17 08:04AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit
Nov-22-17 08:03AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit
Nov-10-17 01:08PM  Dermira, Inc. Value Analysis (NASDAQ:DERM) : November 10, 2017 Capital Cube
08:16AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit
Nov-09-17 05:36PM  Dermira to Present at Upcoming Investor Conferences in November GlobeNewswire
07:54AM  Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : November 9, 2017 Capital Cube
Nov-08-17 08:39AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit -5.97%
Nov-07-17 08:05AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit -7.33%
Nov-06-17 04:49PM  Dermira reports 3Q loss Associated Press
04:03PM  Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis GlobeNewswire
04:01PM  Dermira and UCB Agree to End Collaboration Agreement for CIMZIA GlobeNewswire
08:04AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit
Oct-27-17 08:29AM  Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : October 27, 2017 Capital Cube
Oct-16-17 07:20AM  Corporate News Blog - Dermira Highlights Results from ARIDO Study for Assessment of Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis Patients ACCESSWIRE
Oct-13-17 08:00AM  Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference GlobeNewswire
Oct-11-17 08:42AM  Dermira, Inc. (DERM) Soars: Stock Adds 5.3% in Session Zacks
Oct-10-17 05:22PM  Favorite stock picks from one of Wall Street's top biotech analysts CNBC +5.25%
03:18PM  Allergan trading at a zero pipeline valuation: Evercore's... CNBC Videos
Oct-05-17 08:00AM  Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris GlobeNewswire
Oct-03-17 08:02AM  See what the IHS Markit Score report has to say about Dermira Inc. Markit
Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fust Matthew KDirectorOct 19Sale13.754,00055,00014,051Oct 19 04:24 PM
BAUER EUGENE AChief Medical OfficerAug 15Option Exercise0.006,01209,831Aug 17 04:05 PM
GUGGENHIME ANDREWCOO and CFOAug 15Option Exercise0.008,075019,290Aug 17 04:05 PM
Griffith Christopher M.SVP Head Corp. Dev. & StrategyAug 15Option Exercise0.002,835047,043Aug 17 04:05 PM
WIGGANS THOMAS GCEO & Chairman of the BoardAug 15Option Exercise0.0020,5000100,010Aug 17 04:05 PM
Lyons-Williams LoriChief Commercial OfficerAug 15Option Exercise0.001,06302,984Aug 17 04:05 PM
Pena Luis C.Chief Development OfficerAug 15Option Exercise0.006,500017,047Aug 17 04:06 PM
WIGGANS THOMAS GCEO & Chairman of the BoardJul 09Buy10.0012,000119,95179,510Jul 09 06:57 PM
WIGGANS THOMAS GCEO & Chairman of the BoardJul 02Buy8.7113,780119,99867,510Jul 02 05:04 PM
WIGGANS THOMAS GCEO & Chairman of the BoardJun 25Buy9.8412,150119,58653,730Jun 25 05:40 PM
WIGGANS THOMAS GCEO & Chairman of the BoardJun 18Buy10.1011,875119,95441,580Jun 18 04:19 PM
Nunn Jason RaleighDirectorJun 13Option Exercise0.003,00003,000Jun 14 06:06 PM
MCDADE MARKDirectorJun 13Option Exercise0.003,00003,000Jun 14 05:45 PM
Cohen David EDirectorJun 13Option Exercise0.003,000032,682Jun 14 05:45 PM
Fust Matthew KDirectorJun 13Option Exercise0.003,000018,051Jun 14 05:45 PM
Sebelius KathleenDirectorJun 13Option Exercise0.003,00003,000Jun 14 05:45 PM
CRAVES FRED BDirectorJun 13Option Exercise0.003,00003,000Jun 14 05:46 PM
RINGO WILLIAM RDirectorJun 13Option Exercise0.003,00003,000Jun 14 05:45 PM
WIGGANS THOMAS GCEO & Chairman of the BoardMay 15Option Exercise0.9910,0009,86029,705May 16 06:43 PM
BAUER EUGENE AChief Medical OfficerMar 02Option Exercise1.222,5003,0455,302Mar 06 04:04 PM
BAUER EUGENE AChief Medical OfficerMar 02Sale25.002,50062,5002,802Mar 06 04:04 PM
BAUER EUGENE AChief Medical OfficerMar 01Option Exercise1.225006093,302Mar 02 04:25 PM
BAUER EUGENE AChief Medical OfficerMar 01Sale25.3250012,6582,802Mar 02 04:25 PM
Cohen David EDirectorMar 01Sale25.8560015,51029,682Mar 02 04:25 PM
BAUER EUGENE AChief Medical OfficerFeb 01Option Exercise1.223,0003,6545,802Feb 02 04:46 PM
BAUER EUGENE AChief Medical OfficerFeb 01Sale28.553,00085,6422,802Feb 02 04:46 PM
Cohen David EDirectorFeb 01Sale28.8760017,32230,282Feb 02 04:46 PM
BAUER EUGENE AChief Medical OfficerJan 02Option Exercise1.221,9762,4075,802Jan 04 04:16 PM
Griffith Christopher M.SVP Head Corp. Dev. & StrategyJan 02Option Exercise1.3214,03018,51361,623Jan 04 04:16 PM
Cohen David EDirectorJan 02Sale28.0360016,81830,882Jan 04 04:15 PM
Griffith Christopher M.SVP Head Corp. Dev. & StrategyJan 02Sale27.0518,458499,35443,165Jan 04 04:16 PM
BAUER EUGENE AChief Medical OfficerJan 02Sale27.073,00081,2102,802Jan 04 04:16 PM
WIGGANS THOMAS GCEO & Chairman of the BoardDec 21Option Exercise1.225,0006,09018,662Dec 22 04:16 PM
BAUER EUGENE AChief Medical OfficerDec 18Sale27.343,00082,0113,826Dec 20 04:15 PM
WIGGANS THOMAS GCEO & Chairman of the BoardDec 13Option Exercise0.995,0004,93018,662Dec 15 04:36 PM
WIGGANS THOMAS GCEO & Chairman of the BoardDec 13Sale27.515,000137,56613,662Dec 15 04:36 PM
Cohen David EDirectorDec 01Sale25.4960015,29431,482Dec 05 04:00 PM